The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.

Abstract

BACKGROUND:

Antitumor agents based on platinum have gained a well-established place in the treatment of several forms of cancer. Their efficiency is hampered by serious toxic effects against healthy tissues as well. Ototoxicity is a serious side effect leading to hearing impairment and represents an important issue affecting the patients' quality of life. The currently used platinum chemotherapeutics exert different toxicity towards cochlear cells. The aim of our study was to answer some questions regarding the differential uptake and cellular pharmacodynamics of Cisplatin (CDDP), Carboplatin (CBDCA) and Oxaliplatin (L-OHP) in the HEI-OC1 cochlear cell line.

METHODS:

We studied the expression of copper transporters CTR1, ATP7A and ATP7B which are presumably involved in the uptake, cellular transport and efflux of platinum compounds by immunofluorescence microscopy and flow-cytometry. The cellular uptake of the compounds was evaluated through the determination of intracellular platinum concentration by atomic absorption spectroscopy. The effects of the treatment of HEI-OC1 cells with platinum compounds were also evaluated: cytotoxicity with the Cell Titer Blue viability test, formation of reactive oxygen species with 2',7' -dichlorofluorescein diacetate, genotoxicity with the comet assay and apoptosis with the cleaved PARP ELISA test.

RESULTS:

CTR1, ATP7A and ATP7B were all expressed by HEI-OC1 cells. The treatment with the platinum compounds led to a modulation of their expression, manifested in a differential platinum uptake. Treatment with Cisplatin led to the highest intracellular concentration of platinum compared to Oxaliplatin and Carboplatin at the same dose. Treatment with CuSO4 reduced platinum uptake of all the compounds, significantly in the case of Cisplatin and Carboplatin. CDDP was the most cytotoxic against HEI-OC1 cells, with an IC50 = 65.79  μM, compared to 611.7 μM for L-OHP and 882.9 μM for CBDCA, at the same molar concentration. The production of ROS was the most intense after CDDP, followed by L-OHP and CBDCA. In the comet assay, at the 100 μM concentration, L-OHP and CBDCA induced DNA adducts while CDDP induced adducts as well as DNA strand breaks. CBDCA and L-OHP lead to a significant increase of cleaved PARP at 24h (p < 0.001), suggesting an important apoptotic process induced by these compounds at the used concentrations.

CONCLUSIONS:

The results obtained in the current study suggest that the modulation of copper transporters locally may represent a new strategy against platinum drugs ototoxicity.

• Authors: Maria Perde-Schrepler, Eva Fischer-Fodor, Piroska Virag, Ioana Brie, Mihai Cenariu, Cristian Pop, Angela Valcan, Eugen Gurzau, Alma Maniu
• Journal: Hearing research (Hear Res) Vol. 388 Pg. 107893 (03 15 2020) ISSN: 1878-5891 [Electronic] Netherlands
• PMID: 32006874 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Elsevier B.V. All rights reserved.

Chemical References

• Antineoplastic Agents
• Atp7a protein, mouse
• Copper Transporter 1
• Reactive Oxygen Species
• Slc31a1 protein, mouse
• Oxaliplatin
• Copper
• Carboplatin
• Poly(ADP-ribose) Polymerases
• Atp7b protein, mouse
• Copper-Transporting ATPases
• Cisplatin

Topics

• Animals
• Antineoplastic Agents (metabolism, toxicity)
• Apoptosis (drug effects)
• Carboplatin (metabolism, toxicity)
• Cell Line
• Cisplatin (metabolism, toxicity)
• Cochlea (drug effects, metabolism, pathology)
• Copper (metabolism)
• Copper Transporter 1 (metabolism)
• Copper-Transporting ATPases (metabolism)
• Dose-Response Relationship, Drug
• Mice
• Ototoxicity
• Oxaliplatin (metabolism, toxicity)
• Poly(ADP-ribose) Polymerases (metabolism)
• Reactive Oxygen Species (metabolism)